MedPath

omega-3 supplement in attention deficit hyperactivity disorder

Phase 2
Conditions
Adult ADHD (Attention-deficit hyperactivity disorder ).
Hyperkinetic disorder, unspecified
Registration Number
IRCT2016060128182N2
Lead Sponsor
Kurdistan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
66
Inclusion Criteria

Inclusion Criteria: Diagnosis of ADHD based on DSMIV age between 6-12

Exclusion Criteria

receiving of omega3 suplement during past 6 months; presence of seizures; mental retardation; having any psychiatric disorders

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in Attention-deficit symptoms. Timepoint: Baseline, second, fourth and eighth weeks after intervention. Method of measurement: Conner's and ADHD Rating Scales.;Improvement in Impulsivity symptoms. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Conner's and ADHD Rating Scales–Self-Report.;Improvement in hyperactivity symptome. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Conner's and ADHD Rating Scales–Self-Report.
Secondary Outcome Measures
NameTimeMethod
Severity of ADHD symptoms. Timepoint: Baseline, second, fourth and eighth weeks after intervention. Method of measurement: ADHD Rating Scales, CGI.;Side effect. Timepoint: second, fourth and eighth weeks after intervention. Method of measurement: Side effects quesionnaire.
© Copyright 2025. All Rights Reserved by MedPath